Abstract:The outbreak of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the cause for the ongoing global public health emergency. It is more commonly known as coronavirus disease 2019 (COVID-19); the pandemic threat continues to spread aroundthe world with the fluctuating emergence of its new variants. The severity of COVID-19 ranges from asymptomatic to serious acute respiratory distress syndrome (ARDS), which has led to a high human mortality rate and disruption of socioeconomic well-being. For the restoration of pre-pandemic normalcy, the international scientific community has been conducting research on a war footing to limit extremely pathogenic COVID-19 through diagnosis, treatment, and immunization. Since the first report of COVID-19 viral infection, an array of laboratory-based and point-of-care (POC) approaches have emerged for diagnosing and understanding its status of outbreak. The RT-PCR-based viral nucleic acid test (NAT) is one of the rapidly developed and most used COVID-19 detection approaches. Notably, the current forbidding status of COVID-19 requires the development of safe, targeted vaccines/vaccine injections (shots) that can reduce its associated morbidity and mortality. Massive and accelerated vaccination campaigns would be the most effective and ultimate hope to end the COVID-19 pandemic. Since the SARS-CoV-2 virus outbreak, emerging biotechnologies and their multidisciplinary approaches have accelerated the understanding of molecular details as well as the development of a wide range of diagnostics and potential vaccine candidates, which are indispensable to combating the highly contagious COVID-19. Several vaccine candidates have completed phase III clinical studies and are reported to be effective in immunizing against COVID-19 after their rollout via emergency use authorization (EUA). However, optimizing the type of vaccine candidates and its route of delivery that works best to control viral spread is crucial to face the threatening variants expected to emerge over time. In conclusion, the insights of this review would facilitate the development of more likely diagnostics and ideal vaccines for the global control of COVID-19.

Advanced Vaccine Design Strategies against SARS-CoV-2 and Emerging Variants

Recent Advances in the Molecular Design and Delivery Technology of mRNA for Vaccination against Infectious Diseases

Challenges and Recent Advancements in COVID-19 Vaccines

Engineering Antiviral Vaccines

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

COVID‐19 vaccine: recent advancements and future prospects

Molecular engineering tools for the development of vaccines against infectious diseases: current status and future directions

Challenges and developments in universal vaccine design against SARS-CoV-2 variants

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

COVID-19 Variants and Vaccine Development

Biotechnological Perspectives to Combat the COVID-19 Pandemic: Precise Diagnostics and Inevitable Vaccine Paradigms

Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19)

Current Progress and Challenges in the Design and Development of a Successful COVID-19 Vaccine

Integration of Novel Materials and Advanced Genomic Technologies into New Vaccine Design

Current Progress, Challenges and Prospects in the Development of COVID-19 Vaccines

Functionally Designed Nanovaccines against SARS-CoV-2 and Its Variants

Next-generation COVID-19 Vaccines: Opportunities for Vaccine Development and Challenges in Tackling COVID-19

Protein-based nano-vaccines against SARS-CoV-2: Current design strategies and advances of candidate vaccines